Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151213 | 0.94 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL25434306 | 0.94 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL27753904 | 0.94 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| Ammonia Solution, Strong SCHEMBL4268652 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL27731704 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA7 | |
| Bromide SCHEMBL28158222 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA7 | |
| Bromomethane SCHEMBL27848237 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA7 | |
| Methylamine SCHEMBL27494863 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL10900697 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066632-B1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARM CORP (KR) | 2013-09-04 | — | — | EP | disclosed |
| US-8053439-B2 | Benzophenone derivatives useful for inhibiting formation of microtubule | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-11-08 | — | — | US | disclosed |
| CN-100586932-C | Antitumor compound and its preparation process | INST OF MEDICAL BIOTECHNOLOGY OF CHINESE ACADEMY OF MEDICAL SCIENCES | 2010-02-03 | — | — | CN | disclosed |
| US-20090275575-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-11-05 | — | — | US | disclosed |
| EP-2066632-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | Chong Kun Dang Pharmaceutical Corp. (KR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038955-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2008-04-03 | — | — | WO | disclosed |
| CN-101020654-A | Antitumor compound and its prepn process | INST OF MEDICINE BIOLOGY TECHN (CN) | 2007-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275575-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | TUBB1, TUBA1C, TUBB6 | ACHE 4482/4885SMN1; SMN2 1781/4885CA12 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.